DRKS00003069
Recruiting
Not Applicable
on-interventional study for recording the treatment and the influence on the treatment-specific quality of life with patients with hormone-refractory prostate cancer under a Docetaxel (Eurotere®) containing chemotherapy. - ProQoLTere
apharm GmbH0 sites500 target enrollmentMay 2, 2011
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hormone Refractory Prostate Cancer
- Sponsor
- apharm GmbH
- Enrollment
- 500
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically confirmed hormone\-refractory prostate cancer.
- •Signed patient informed consent form.
Exclusion Criteria
- •Other malignant diseases in the past 5 years,
- •Lack of compliance.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Collection of data on the use of a VWF/FVIII concentrate (wilate®) in all clinical applications in von Willebrand diseaseISRCTN11568655Octapharma GmbH120
Active, not recruiting
Not Applicable
on-interventional study on management of treatment and safety in patients with secondary immunodeficiency due to haematological malignancies treated with Ig Vena according to the approved therapeutic indicationsD84.9C90.0C91.1Immunodeficiency, unspecifiedMultiple myelomaChronic lymphocytic leukaemia of B-cell typeDRKS00016556Kedrion S.p.A.25
Completed
Not Applicable
on-interventional retrospective study to evaluate the menstrual cycle profiles and quality of life of women after the use of the new vaginal ring GinoRing® delivering 0.120mg etonogestrel and 0.015mg ethinylestradiol per dayN92.0Excessive and frequent menstruation with regular cycleDRKS00014982Exeltis Germany GmbH103
Recruiting
Phase 1
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (CODEBREAK)locally-advanced and unresectable or metastatic NSCLC with KRAS G12CMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 25.1Level: LLTClassification code: 10069759Term: KRAS mutation Class: 10018065Therapeutic area: Diseases [C] - Neoplasms [C04]Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]CTIS2024-510837-16-00Institut Gustave Roussy40
Active, not recruiting
Phase 1
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic non-small-cell lung cancerocally-advanced and unresectable or metastatic non-small-cell lung cancer with KRAS G12C mutationTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-006958-31-FRGustave Roussy40